Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1

Biochemical Pharmacology

Volumn 78, Issue 5, 2009, Pages 514-522

  Bauvois, B ^a,b,c,d   Nguyen, J ^d   Tang, R ^a,e   Billard, C ^a,b,c   Kolb, J P ^a,b,c  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS   (France)

^e HÔTEL DIEU   (France)

Author keywords

Acute myeloid leukemia; Antigen presenting cells; B7.1; IRF 1

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BETA INTERFERON; CD40 ANTIGEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA TRANSCRIPTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIGENS, CD80; BASE SEQUENCE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERFERON REGULATORY FACTOR-1; INTERFERON TYPE I; INTERFERON-GAMMA; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 67649482305     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.005     Document Type: Article

References (52)

1. Carreno B.M., Carter L.L., and Collins M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol 5 4 (2005) 424-430
2. Santilli F., Basili S., Ferroni P., and Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2 4 (2007) 256-268
3. Wang S., and Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 6 8 (2004) 759-766
4. Hirano N., Takahashi T., Ohtake S., Hirashima K., Emi N., Saito K., et al. Expression of costimulatory molecules in human leukemias. Leukemia 10 7 (1996) 1168-1176
5. Costello R.T., Mallet F., Sainty D., Maraninchi D., Gastaut J.A., and Olive D. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol 28 1 (1998) 90-103
6. Zheng Z., Takahashi M., Aoki S., Toba K., Liu A., Osman Y., et al. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. J Exp Clin Cancer Res 17 3 (1998) 251-258
7. Vollmer M., Li L., Schmitt A., Greiner J., Reinhardt P., Ringhoffer M., et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 120 6 (2003) 1000-1008
8. Li L., Schmitt A., Reinhardt P., Greiner J., Ringhoffer M., Vaida B., et al. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Cancer Immunol 3 (2003) 8
9. Ugurel S., Lindemann M., Schadendorf D., and Grosse-Wilde H. Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?. Cancer Immunol Immunother 53 11 (2004) 1051
10. Chaux P., Moutet M., Faivre J., Martin F., and Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74 5 (1996) 975-983
11. Ward R.C., and Kaufman H.L. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol 26 3-4 (2007) 161-196
12. Mutis T., Schrama E., Melief C.J., and Goulmy E. CD80-transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood 92 5 (1998) 1677-1684
13. Stripecke R., Cardoso A.A., Pepper K.A., Skelton D.C., Yu X.J., Mascarenhas L., et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96 4 (2000) 1317-1326
14. Notter M., Willinger T., Erben U., and Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 97 10 (2001) 3138-3145
15. Parmar S., and Platanias L.C. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 15 6 (2003) 431-439
16. Borden E.C. Review: Milstein Award lecture: interferons and cancer: where from here?. J Interferon Cytokine Res 25 9 (2005) 511-527
17. Obeid D., and Bauvois B. Interferons: mechanisms, biological activities and survey of their use in human disease. Curr Bioactive Compds 2 (2006) 431-444
18. Kalvakolanu D.V. Alternate interferon signaling pathways. Pharmacol Ther 100 1 (2003) 1-29
19. Li Y., Srivastava K.K., and Platanias L.C. Mechanisms of type I interferon signaling in normal and malignant cells. Arch Immunol Ther Exp (Warsz) 52 3 (2004) 156-163
20. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75 2 (2004) 163-189
21. Paun A., and Pitha P.M. The IRF family, revisited. Biochimie 89 6-7 (2007) 744-753
22. Langer J.A., Cutrone E.C., and Kotenko S. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 15 1 (2004) 33-48
23. Marijanovic Z., Ragimbeau J., van der Heyden J., Uze G., and Pellegrini S. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J 407 1 (2007) 141-151
24. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., and Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178 2 (1993) 669-674
25. Marckmann S., Wiesemann E., Hilse R., Trebst C., Stangel M., and Windhagen A. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol 138 3 (2004) 499-506
26. Nguyen V.T., and Benveniste E.N. Critical role of tumor necrosis factor-alpha and NF-kappa B in interferon-gamma-induced CD40 expression in microglia/macrophages. J Biol Chem 277 16 (2002) 13796-13803
27. Wagner A.H., Gebauer M., Pollok-Kopp B., and Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99 2 (2002) 520-525
28. Zhao Z., Qian Y., Wald D., Xia Y.F., Geng J.G., and Li X. IFN regulatory factor-1 is required for the up-regulation of the CD40-NF-kappa B activator 1 axis during airway inflammation. J Immunol 170 11 (2003) 5674-5680
29. Freedman A.S., Freeman G.J., Rhynhart K., and Nadler L.M. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 137 2 (1991) 429-437
30. Creery W.D., Diaz-Mitoma F., Filion L., and Kumar A. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol 26 6 (1996) 1273-1277
31. Clavreul A., D'Hellencourt C.L., Montero-Menei C., Potron G., and Couez D. Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes. Immunology 95 2 (1998) 272-277
32. Bauvois B., Van Weyenbergh J., Rouillard D., and Wietzerbin J. TGF-beta 1-stimulated adhesion of human mononuclear phagocytes to fibronectin and laminin is abolished by IFN-gamma: dependence on alpha 5 beta 1 and beta 2 integrins. Exp Cell Res 222 1 (1996) 209-217
33. Bauvois B., Dumont J., Mathiot C., and Kolb J.P. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 16 5 (2002) 791-798
34. Yeow W.S., Au W.C., Juang Y.T., Fields C.D., Dent C.L., Gewert D.R., et al. Reconstitution of virus-mediated expression of interferon alpha genes in human fibroblast cells by ectopic interferon regulatory factor-7. J Biol Chem 275 9 (2000) 6313-6320
35. Park H.Y., Park J.Y., Kim J.W., Lee M.J., Jang M.J., Lee S.Y., et al. Differential expression of dendritic cell markers by all-trans retinoic acid on human acute promyelocytic leukemic cell line. Int Immunopharmacol 4 13 (2004) 1587-1601
36. Ruiz-Ruiz C., Ruiz de Almodovar C., Rodriguez A., Ortiz-Ferron G., Redondo J.M., and Lopez-Rivas A. The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 279 19 (2004) 19712-19720
37. Sanceau J., Boyd D.D., Seiki M., and Bauvois B. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem 277 38 (2002) 35766-35775
38. Rosewicz S., Detjen K., Scholz A., and von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 80 Suppl. 1 (2004) 85-93
39. Takano S., Kamiyama H., Tsuboi K., and Matsumura A. Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol 21 2 (2004) 69-73
40. Wu W.Z., Sun H.C., Shen Y.F., Chen J., Wang L., Tang Z.Y., et al. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 131 3 (2005) 169-178
41. Genin P., Morin P., and Civas A. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J Virol 77 12 (2003) 7113-7119
42. Reischl I.G., Pollabauer E.M., Peiritsch S., Schlager S., Gladstone P., Vooijs W.C., et al. The 'monocytic' cell line I937 displays typical B cell characteristics. Immunol Lett 49 1-2 (1996) 127-131
43. Stonehouse T.J., Woodhead V.E., Herridge P.S., Ashrafian H., George M., Chain B.M., et al. Molecular characterization of U937-dependent T-cell co-stimulation. Immunology 96 1 (1999) 35-47
44. Lim W., Gee K., Mishra S., and Kumar A. Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells. J Immunol 175 9 (2005) 5690-5700
45. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 5573 (2002) 1634-1635
46. Zhao J., Freeman G.J., Gray G.S., Nadler L.M., and Glimcher L.H. A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. J Exp Med 183 3 (1996) 777-789
47. Nguyen J., Knapnougel P., Lesavre P., and Bauvois B. Inhibition of matrix metalloproteinase-9 by interferons and TGF-beta1 through distinct signalings accounts for reduced monocyte invasiveness. FEBS Lett 579 25 (2005) 5487-5493
48. Benjamin R., Khwaja A., Singh N., McIntosh J., Meager A., Wadhwa M., et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 109 3 (2007) 1244-1247
49. Schmidt M., Nagel S., Proba J., Thiede C., Ritter M., Waring J.F., et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91 1 (1998) 22-29
50. Guzman M.L., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood 97 7 (2001) 2177-2179
51. Boultwood J., Fidler C., Lewis S., MacCarthy A., Sheridan H., Kelly S., et al. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. Blood 82 9 (1993) 2611-2616
52. Klein G., Vellenga E., Fraaije M.W., Kamps W.A., and de Bont E.S. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50 2 (2004) 87-100